Shivalik Rasayan is a manufacturer of agrochemicals and APIs; it has a production capacity of 21,550 MT; and claims to be the largest producer of Dimethoate Technical and the second largest producer of Malathion in India. Its manufacturing facilities are located at Dehradun, Uttarakhand and Dahej, Gujarat; it has a dedicated R&D centre at Bhiwadi, … Continue reading Analysis – Shivalik Rasayan
Exploring the Investment Opportunities of 'Indian Toners and Developers', 'Parnax Lab', and 'Emmbi Industries'.
Reviewing the Investment Prospects of LG Balakrishnan & Bros., Control Print, and Pakka Post their September 2024 quarter results.
Reviewing the Investment Prospects of Kovai Medical Center, Natural Capsules, and Dynemic Products post their September 2024 quarter results
The wood-panel sector has seen strong stock performances but currently faces elevated valuations limiting returns. Century Plyboard and Stylam Industries led with high returns, while Rushil Décor’s low valuation appears misjudged. Greenlam Industries exhibit mediocre fundamentals despite some strengths. Overall, caution is advised due to high current stock prices.
A Few Companies with Differentiated Business Models led by Innovative and Enterprising Management offer Good Investment Opportunities.
Reviewing the Investment Prospects of Associated Alcohols and Dynemic Products. Conditions become favourable for sustainable earnings growth when a firm with a strong competitive position through productive capital allocation achieves superior operating profitability.
Prospecting for New Opportunities Among Five Stocks. There is no point in being invested in an idea one is not excited about. We are in a stock market boom, all stocks are rising, so the recent better performance of a stock might be reflecting the general euphoria and thus have nothing to do with its fundamentals.
We decided to buy the stock of L G Balakrishnan & Bros (LGBB) when we first discussed the stock in April 2023. Its market price then - ₹745 per share - was at a significant discount to our estimated fair value of ₹1,257 per share. When we reviewed the stock again almost one year later, … Continue reading L G Balakrishnan & Bros: There is Still Value in the Stock
‘HOLD’ was our decision on Lincoln Pharma when we last reviewed the stock in February 2024 as the market price then (₹690 per share) was slightly higher than our estimated fair value. Major headwinds perceived then were the persistently slow pace of earnings growth, sluggish capital allocation, and mediocre working capital management. Now six months … Continue reading Lincoln Pharma: Despite Recent Gains Odds Seem Favourable
AMN CAPITAL 